Current CV .
My objective is to obtain a rewarding and challenging research scientist position where my background and experience will contribute to the success of a growing company or research center.
Currently, I am a Senior Associate Scientist at Amgen Inc. and certified Molecular Biologist with the American Society of Clinical Pathology MB (ASCP). I have more than 10 years of experience in the biotechnology/ pharmaceutical industry. I am highly proficient in various lab techniques, technologies, and automation. I demonstrated consistent success in the execution of assay development and method validation activities supporting clinical stage programs within GCP and GLP regulated environments. I possess extensive experience in optimization and validation of drug potency assays (ELISA and cell based assays), protein purification and characterization, and DNA/RNA extraction and quantitation. I am a subject matter expertise in the areas of human and rodent cell lines propagation and tissue dis-aggregation. I have proven operational capabilities in the establishment of standard operating procedures to ensure our laboratory meets regulatory and business requirements.
I am a self-motivated professional who works effectively as an individual contributor or within a team matrix. As a quick learner, I can efficiently deliver results, easily adapt to changing environment and provide fresh ideas. My strengths include statistical analysis/guidance, report writing, and communication.
Thank you in advance for your consideration. Please feel free to call me at (805-990-6258), or by e-mail at (mahawally46@gmail.com) if you have questions or would like a list of references.
Sincerely,
Maha Rizk
Overview Radboudumc Center for Proteomics, Glycomics and Metabolomics april 2015Alain van Gool
An overview of the proteomics, glycomics and metabolomics expertise and capabilities within the Translational Metabolic Laboratory of the Radboudumc. We're interested in collaboration with academic and industrial partners, either bilateral or as part of multi-partner consortia.
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3b3Tbcd
Measurement of host cell proteins is vital to ensuring a biotherapy's purity and a patient's safety. Biotherapies treat diseases with products produced by living organisms, as a result, host cell components must be characterized and controlled. We'll review new methods within product characterization for detection.
Trace amounts of host cell proteins can be present after the production and purification of any biopharmaceutical. Detection of these species requires highly specific techniques to accurately quantify even low levels of contamination. Host cell protein impurities, present at PPM-levels in biotherapies, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. Their complex and diverse nature makes them challenging to detect or monitor. With acceptance criteria for host residual DNA usually set at a very low level (often =1.0 pg of DNA per mg of drug substance), effective removal techniques and sensitive methods of detection are critical.
Antibody-based techniques, like the enzyme-linked immunosorbent assay (ELISA), have been used to assess the HCP load of biotherapeutics before and after process changes. However, these techniques do not necessarily detect qualitative changes in the HCP population. In this webinar, we will discuss how mass spectrometry (MS)-based approaches coupled with ELISA methods help detect qualitative and quantitative differences in HCP populations.
In this webinar, you will learn:
• Comprehensive HCP ID and semi-quantitation
• HC agnostic process
• Creation of process specific database
• Differential clearance of specific HCPs throughout purification steps
• Monitoring of problematic species e.g. immunogenic (PLBL2), lipases and proteases
• Explanation about why 90% of BLAs filed included this HCP MS data
Historically, genetic toxicology has been comprised of bacterial and cell based in vitro assays such as the Ames assay (a bacterial mutagenicity assay), Micronucleus and Chromosomal Aberration assays (mammalian cytogenetic assays), and Mouse Lymphoma Assay (in vitro mammalian cell gene mutation assay). These were routinely used for safety evaluation and are still part of the standard core battery. The emergence of new technologies has facilitated the development of in vitro methods for safe and effective drug and chemical testing.
This BioReliance® toxicology services webinar will explore alternative models, including 3D skin models that comply with the EC Scientific Committee on Consumer Safety (SCCS) recommendations. It will also discuss how the 3Rs (Replace, Reduce, Refine) Principle advocates the exploration of such alternative methods while achieving required goals.
In this webinar, you will learn:
• About in vitro alternatives to animal toxicity testing in pharma, chemical, tobacco, and personal care products.
• How the 3Rs (Replace, Reduce, Refine) Principle advocates exploring alternative methods without compromising the required goals.
• Alternatives to comply with the 7th Amendment to the EC Cosmetics Directive.
Current CV .
My objective is to obtain a rewarding and challenging research scientist position where my background and experience will contribute to the success of a growing company or research center.
Currently, I am a Senior Associate Scientist at Amgen Inc. and certified Molecular Biologist with the American Society of Clinical Pathology MB (ASCP). I have more than 10 years of experience in the biotechnology/ pharmaceutical industry. I am highly proficient in various lab techniques, technologies, and automation. I demonstrated consistent success in the execution of assay development and method validation activities supporting clinical stage programs within GCP and GLP regulated environments. I possess extensive experience in optimization and validation of drug potency assays (ELISA and cell based assays), protein purification and characterization, and DNA/RNA extraction and quantitation. I am a subject matter expertise in the areas of human and rodent cell lines propagation and tissue dis-aggregation. I have proven operational capabilities in the establishment of standard operating procedures to ensure our laboratory meets regulatory and business requirements.
I am a self-motivated professional who works effectively as an individual contributor or within a team matrix. As a quick learner, I can efficiently deliver results, easily adapt to changing environment and provide fresh ideas. My strengths include statistical analysis/guidance, report writing, and communication.
Thank you in advance for your consideration. Please feel free to call me at (805-990-6258), or by e-mail at (mahawally46@gmail.com) if you have questions or would like a list of references.
Sincerely,
Maha Rizk
Overview Radboudumc Center for Proteomics, Glycomics and Metabolomics april 2015Alain van Gool
An overview of the proteomics, glycomics and metabolomics expertise and capabilities within the Translational Metabolic Laboratory of the Radboudumc. We're interested in collaboration with academic and industrial partners, either bilateral or as part of multi-partner consortia.
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3b3Tbcd
Measurement of host cell proteins is vital to ensuring a biotherapy's purity and a patient's safety. Biotherapies treat diseases with products produced by living organisms, as a result, host cell components must be characterized and controlled. We'll review new methods within product characterization for detection.
Trace amounts of host cell proteins can be present after the production and purification of any biopharmaceutical. Detection of these species requires highly specific techniques to accurately quantify even low levels of contamination. Host cell protein impurities, present at PPM-levels in biotherapies, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. Their complex and diverse nature makes them challenging to detect or monitor. With acceptance criteria for host residual DNA usually set at a very low level (often =1.0 pg of DNA per mg of drug substance), effective removal techniques and sensitive methods of detection are critical.
Antibody-based techniques, like the enzyme-linked immunosorbent assay (ELISA), have been used to assess the HCP load of biotherapeutics before and after process changes. However, these techniques do not necessarily detect qualitative changes in the HCP population. In this webinar, we will discuss how mass spectrometry (MS)-based approaches coupled with ELISA methods help detect qualitative and quantitative differences in HCP populations.
In this webinar, you will learn:
• Comprehensive HCP ID and semi-quantitation
• HC agnostic process
• Creation of process specific database
• Differential clearance of specific HCPs throughout purification steps
• Monitoring of problematic species e.g. immunogenic (PLBL2), lipases and proteases
• Explanation about why 90% of BLAs filed included this HCP MS data
Historically, genetic toxicology has been comprised of bacterial and cell based in vitro assays such as the Ames assay (a bacterial mutagenicity assay), Micronucleus and Chromosomal Aberration assays (mammalian cytogenetic assays), and Mouse Lymphoma Assay (in vitro mammalian cell gene mutation assay). These were routinely used for safety evaluation and are still part of the standard core battery. The emergence of new technologies has facilitated the development of in vitro methods for safe and effective drug and chemical testing.
This BioReliance® toxicology services webinar will explore alternative models, including 3D skin models that comply with the EC Scientific Committee on Consumer Safety (SCCS) recommendations. It will also discuss how the 3Rs (Replace, Reduce, Refine) Principle advocates the exploration of such alternative methods while achieving required goals.
In this webinar, you will learn:
• About in vitro alternatives to animal toxicity testing in pharma, chemical, tobacco, and personal care products.
• How the 3Rs (Replace, Reduce, Refine) Principle advocates exploring alternative methods without compromising the required goals.
• Alternatives to comply with the 7th Amendment to the EC Cosmetics Directive.
Next Generation Sequencing for Identification and Subtyping of Foodborne Pat...Nathan Olson
"Next Generation Sequencing for Identification and Subtyping of Foodborne Pathogens" presentation at the Standards for Pathogen Identification via NGS (SPIN) workshop hosted by the National Institute for Standards and Technology October 2014 by Rebecca Lindsey, PhD from Enteric Diseases Laboratory Branch of the CDC.
Vaccine Cell Bank and Virus Seed CharacterizationMilliporeSigma
In this webinar, you will learn:
- about the importance of characterising cell banks and virus seed stocks in order to meet worldwide regulatory requirements.
- the difference between guidance documents from different organizations worldwide
- new technologies for determining the identity of cell substrates and virus seed stocks
- detecting adventitious agent contamination
"Microbial Genomics @NIST" presentation at the Standards for Pathogen Identification via NGS (SPIN) workshop hosted by the National Institute for Standards and Technology October 2014 by Nathan Olson from NIST.
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3icKkbZ
Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays.
Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors.
This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50.
In this webinar, you will learn:
• Critical biosafety considerations for AAV vectors based on the latest regulatory guidance
• How replication competent AAV testing fits into your bulk and final release testing package
• The benefits of routine and platform assays over custom assay development
Presented by:
Steven McDade, Senior Technical Specialist, Field Technology Management
Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services
Setting up for successful lot release testing by Edmund AngMilliporeSigma
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Unit 9 IN VITRO EXPERIMENTATION: ADVANTAGES & DISADVANTAGESPHARMA IQ EDUCATION
INTRODUCTION TO IN-VITRO STUDIES
DIFFERENCES BETWEEN IN VITRO & IN VIVO
APPLICATIONS OF IN VITRO STUDIES
ADVANTAGES OF IN VITRO STUDIES
DISADVANTAGES OF IN VITRO STUDIES
Protein microarray Preparation of protein microarray Different methods of arr...naveed ul mushtaq
Protein microarray
Preparation of protein microarray
Different methods of arraying the proteins.FUNCTIONAL PROTEIN MICROARRAYSAnalytical microarrays:-
3.REVERSE PHASE PROTEIN MICROARRAY APPLICATIONS:-
A high-throughput approach for multi-omic testing for prostate cancer researchThermo Fisher Scientific
The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA).
Next Generation Sequencing for Identification and Subtyping of Foodborne Pat...Nathan Olson
"Next Generation Sequencing for Identification and Subtyping of Foodborne Pathogens" presentation at the Standards for Pathogen Identification via NGS (SPIN) workshop hosted by the National Institute for Standards and Technology October 2014 by Rebecca Lindsey, PhD from Enteric Diseases Laboratory Branch of the CDC.
Vaccine Cell Bank and Virus Seed CharacterizationMilliporeSigma
In this webinar, you will learn:
- about the importance of characterising cell banks and virus seed stocks in order to meet worldwide regulatory requirements.
- the difference between guidance documents from different organizations worldwide
- new technologies for determining the identity of cell substrates and virus seed stocks
- detecting adventitious agent contamination
"Microbial Genomics @NIST" presentation at the Standards for Pathogen Identification via NGS (SPIN) workshop hosted by the National Institute for Standards and Technology October 2014 by Nathan Olson from NIST.
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3icKkbZ
Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays.
Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors.
This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50.
In this webinar, you will learn:
• Critical biosafety considerations for AAV vectors based on the latest regulatory guidance
• How replication competent AAV testing fits into your bulk and final release testing package
• The benefits of routine and platform assays over custom assay development
Presented by:
Steven McDade, Senior Technical Specialist, Field Technology Management
Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services
Setting up for successful lot release testing by Edmund AngMilliporeSigma
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Unit 9 IN VITRO EXPERIMENTATION: ADVANTAGES & DISADVANTAGESPHARMA IQ EDUCATION
INTRODUCTION TO IN-VITRO STUDIES
DIFFERENCES BETWEEN IN VITRO & IN VIVO
APPLICATIONS OF IN VITRO STUDIES
ADVANTAGES OF IN VITRO STUDIES
DISADVANTAGES OF IN VITRO STUDIES
Protein microarray Preparation of protein microarray Different methods of arr...naveed ul mushtaq
Protein microarray
Preparation of protein microarray
Different methods of arraying the proteins.FUNCTIONAL PROTEIN MICROARRAYSAnalytical microarrays:-
3.REVERSE PHASE PROTEIN MICROARRAY APPLICATIONS:-
A high-throughput approach for multi-omic testing for prostate cancer researchThermo Fisher Scientific
The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA).
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using
a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
2014 11-27 ODDP 2014 course, Amsterdam, Alain van GoolAlain van Gool
Presentation as part of a comprehensive oncology drug development course, to discuss a pharmaceutical approach to identify, validate and develop biomarkers for personalized medicine for melanoma.
1. MAHA W. RIZK
150 Majestic Court, 1105 • Moorpark, California 93021
Home: (805) 552-4266 • mahawally46@gmail.com • Cell: (805) 990-6258
QUALIFICATIONS SUMMARY
Senior-level Researcher with more than ten years experience in biotechnology / pharmaceutical environments.
Exceptional research background in oncology biomarkers, the early stages of drug discovery, preclinical studies,
and clinical trials. Proven capabilities in writing detailed research reports with statistical analysis and
recommendations. Self-motivated professional who works independently and also collaborates on teams.
Articulate communicator with all organizational levels.
Expertise includes:
Oncology/ inflammation Biomarker assay development and GLP-like assay validation
Evaluate drug candidates’ specificity and selectivity by various technologies including FACS, total protein
analysis by Western Blot, ELISA and MSD
Cell lines propagation, cell banking and tissue disaggregation
DNA/RNA extraction and quantitation from fresh tissue and FFPE to support microarray investigations for
molecular signature that predict response to drug candidates
Use the Nautilus LIMS for maintaining samples chain of custody and samples data analysis
RELPOT Plus, SoftMax, GraphPad Prism and SnagIT-8 data capture software Statistical Packages
Microsoft Office Suite (Excel, Word, PowerPoint, Outlook)
TECHNICAL EXPERIENCE
Oncology and Inflammation Research
Fine Needle Aspirate assay development to investigate RANK/L expression by IHC in NSCLC
DNA and RNA extractions from control cell lines and FFPE blocks to investigate multiple biomarkers for
AMGEN programs
Assist in developing Treg subsets and MDSC biomarkers on FACSCanto II for inflammatory responses
siRNA transfection
Utilize ELISA and MSD assays for biomarker screening and quantitation
Conduct cytotoxicity screening using vascular permeability and MTT cell proliferation assays.
Analytical Chemistry
Conduct protein extractions and purification using varieties of chromatographic techniques.
Perform Protein quantitation using Molecular Dynamics Storm 860, BCA, Bradford, and Lowery methods.
Complete Radiometric Enzymes activity assays using Beckman Coulter Biomek 3000 and 1450 MicroBeta
liquid scintillation counter.
Execute Novel protein characterization using Iso-Electric Focusing, SDS-PAGE gel electrophoresis, Western
Blot, and UV absorbance.
Monitor protein purification steps using Coomassie and Silver staining SDS-PAGE.
Analyze kidney, liver, and electrolyte functions via Dade Behring Dimension.
2. Maha W. Rizk • Page Two
Hematology and Hemostasis
Compile Clinical Hematology and cytology analysis for preclinical studies utilizing Advia 120 Hematology
Analyzer with Multispecies Package (Bayer Diagnostics).
Use FORCYTE Veterinary Hematology Analyzer (Oxford Science, Inc.) plus Hemavet Hematology Analyzers
(Drew Scientific Group, Inc.).
LABORATORY MANAGEMENT EXPERIENCE
Laboratory Management
Negotiate reagents’ standing order with third party
Serve as member of Drug Discovery Platform, which identifies new technologies that would benefit the
organization research group.
Serve as member of Assay Qualification Assessment Group (AQAG) to review the newly developed biomarker
assays
Write and submit new equipment requests that are reviewed by Capital Equipment Budget Committee.
Supervise and train summer students.
EDUCATION
UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, California
Molecular Biologist MB (ASCP) certificate #1879
SHORELINE COMMUNITY COLLEGE, Seattle, Washington
Biotechnology Laboratory Specialist Certificate
AIN SHAMS UNIVERSITY, Cairo, Egypt
Bachelor of Science in Biochemistry
PROFESSIONAL / RESEARCH EXPERIENCE
AMGEN CORPORATION. – THOUSAND OAKS, California 12/2008 – Present
Sr Associate Scientist– Oncology Biomarkers (12/2008-Present)
Perform assays quantification and validation for Amgen programs focus on Oncology, inflammation and
neuroscience drug candidates
Developing Fine Needle Aspirate methodology to investigate RANK/ RANKL expression in ex-vivo NSCLC by
IHC that will aid in patients stratification and lung cancer therapy.
Isolate DNA and RNA from flash frozen tissues, human cell lines and FFPE blocks to support microarray
investigations for molecular signature that predict response to drug candidates
Tissue disaggregation and isolation of viable cells for FACS assays, protein purification from cell line and human
tissues, cell culture, cell based kinase assays, whole tissue enzymatic assays, and GLP-like assay validation.
Propagate, maintain mammalian cell culture, siRNA transfection optimization, cellular toxicity assays and
validation, RNA purification and quantification
Other Duties: Track in house AMGEN donors and FFPE blocks and clinical samples clinical samples chain of
custody using Nautilus tracking system
3. Maha W. Rizk • Page Three
PROFESSIONAL / RESEARCH EXPERIENCE (CONTINUED)
Collaborate with Amgen operation group for medical science manual and automated pipettes calibration tracking,
report out of tolerance pipettes and follow up with the primary investigator for clinical samples’ assessment study
PATHWAY DIAGNOSTICS. – MALIBU, California 11/2007 – 12/2008
Scientist I– Virology (11/2007-12/2008)
Create Master Cell bank and subsequent Working cell bank for HEp2 cell line.
Infect HEp2 cell line with Respiratory Syncytial virus to creat PDX virus stock
Perform Microneutralization Assay for anti RSV antibody quantitation
Perform Respiratory viruses screening and identification for clinical trial samples
Quantify the biological activity of PI88 in plasma samples by Fluorescence Quenching Assay
Write SOPs for PDX cell culture propagation and maintenance , assays qualification followed by the validation
plan
ACT-1 AMGEN INC. – Thousand Oaks, California 04/2007 – 11/2007
Senior Research Associate – Global Cellular and Analytical Resources (04/2007-10/26/07)
Potency quantification of Amgen compounds
Perform quantification of Amgen anti –IL17 and anti-glucagon receptors
Quantify the biological activity of anti EGF receptor by Gene expression bioassay
Maintain and propagate HuGR11-10, CHO, HFF and MRE cell lines
Analyze the raw data using AMGEN controlled spreadsheet RelPot Plus and SoftMax programs
ELI-LILLY (formerly ICOS CORP.), Bothell, Washington 1999 – 2007
Senior Research Associate – Preclinical Department (2001-2007)
Biomarker Identification and Assay Development
Perform cytokine quantitation (multiple species) for serum, tissue homogenates, and bronchoalveolar lavage
using standard ELISA, MESO-Scale electrochemiluminescence, and Multiplex Cytometric Bead Array.
Conduct in vitro vascular permeability and MTT proliferation assays to mimic the target tissue for the testing
compound toxicity, as part of Pre-IND filing.
Implement insulin quantitation for pre- and post-treated rat pancreatic β-cell culture using standard ELISA.
Process Development
Perform Sequential Lipoprotein Depletion and Radiometric enzyme activity assay for recombinant platelet-
activating factor acetylhydrolase (rPafase)® plasma levels in support of a phase 2 clinical trial.
Develop and manufacture in-house HDL reagent for Lipoprotein Binding Assay (Immunoaffinity purification of
Apolipoprotein A1-HDL utilizing CNBr-activated sepharose 4 fast flow conjugated to anti-Apo A1 antibody).
Utilize Ion Exchange Chromatography and Size Exclusion Chromatography as part of rPafase cross
characterization plan.
Revise QC test methods to improve separations of pure species of rPafase pre, main, and post peaks.
Clinical Pathology
Perform routine hematology assessment on humans and animals, including automated analysis, and manual
differentials for efficacy and toxicity studies.
Conduct routine clinical chemistry assessment on humans and animals.
4. Maha W. Rizk • Page Four
PROFESSIONAL / RESEARCH EXPERIENCE (CONTINUED)
Execute manual cytology examination of bronchoalveolar lavage fluids, as part of evaluating compound efficacy
in murine model of allergic bronchitis.
Compile statistics, generate graphs, and prepare text reports of hematology, clinical chemistry, and cytology
results for submission to investigators.
Evaluate clinical pathology endpoints (clinical chemistry, hematology, and cytology) for investigational efficacy,
tolerability, and toxicity studies performed in-house.
Monitor reagent and supplies inventory and place electronic supply orders.
Participate in product research and prepare proposal and justification for acquiring new lab equipment that
considerably speed up performance and accuracy.
Implement Laboratory Information System (LIS) (LabCat, Innovative Programming Associates, Princeton, NJ).
Research Associate – Research Department (1999-2001)
Protein Biochemistry
Develop purification methods for recombinant proteins expressed in mammalian cells, E. coli, and Baculovirus /
insect cell culture.
Perform cell lysis using Frensh Press, Sonication, and dounce homogenization.
Prepare protein extraction using Saturated Ammonium Sulfate Cuts, ultra filtration, and dialysis.
Use basic chromatographic techniques for large scale purification (metal chelate affinity chromatography, biotin-
streptavidin affinity chromatography, gel filtration, ion exchange, hydrophobic interaction, protein affinity
chromatography, and size exclusion chromatography).
Conduct novel proteins characterization expressed in various cell types by Iso-Electric Focusing, SDS-PAGE gel
electrophoresis, Western Blot, UV absorbance, and protein quantitation (BCA, Bradford, and Lowery methods).
Develop enzyme labeled Ni-NTA conjugate plate based assay for measuring His-Tag proteins in raw materials.
THE GENETIC INSTITUTE, Pasadena, CA 1992
Laboratory Technician
Perform amniocentesis chromosomes analysis for paternity testing and genetic birth defects.
Conduct enzyme immunoassay to evaluate patient thyroid status.
Collect patient samples, oversee laboratory purchasing / receiving, and maintain records / inventory.
VETERANS ADMINISTRATION HOSPITAL MEDICAL CENTER, Sepulveda, CA 1991
Laboratory Technician
Collect patient samples and perform routine clinical chemistry analysis.
Conduct manual cytology examinations for urine samples.
Perform data entry and patient recordkeeping.
TRAINING / CERTIFICATION
E-Workbook online-Point of contact for Oncology Biomarkers Group
Diagnostic Hybrids Respiratory viruses Screening and Identification training
AMGEN Hazard Communication and chemical hygiene training.
5. Maha W. Rizk • Page Five
TRAINING / CERTIFICATION (CONTINUED)
AMGEN GLP / GMP Training
Laboratory Leadership and Management Workshop (Washington Biotechnology and Biomedical Association)
Technical Writing Course (IWCC Training in Communications)
Scientific Presentation Course (IWCC Training in Communications)
Bayer Advia 120 Basic and Multi-species Training and Certification
Certified Phlebotomy 80-hour Training Course
PROFESSIONAL AFFILIATION
American Association Of Clinical Pathology (ASCP)
California Biotechnology and Biomedical Association (CABIO)
Washington Biotechnology and Biomedical Association (WBBA)
PUBLICATION
Redundancy of growth factor utilization and complex molecular analyses in human primary tumors highlights
potential resistance mechanisms for targeted agents
John Rossi, Robert D. Loberg, Michael B. Bass, Chetan Deshpande, Dan Baker, Maha Rizk, Katherine
Paweletz, Michael A. Damore, Scott D. Patterson, Ian McCaffery